Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne™ Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.
"Multiple myeloma is a treatable, but ultimately incurable, blood cancer that eventually becomes resistant to all currently available therapies," said Dr. Lesokhin. "Advances in clinical next-generation sequencing have made it possible to rapidly identify genomic alterations that may be driving a patient's cancer and could inform treatment options leading to advances in clinical development of new targeted therapies in multiple myeloma patients."
In this study, researchers at Memorial Sloan-Kettering used FoundationOne Heme to analyze whole bone marrow aspirate samples from 28 newly diagnosed and 27 heavily pre-treated multiple myeloma patients. High coverage and high quality sequence data was obtained in 98% (54/55) of cases, and alteration prevalence was examined in 63% of (35/55) samples with sufficient plasma cell content. In the analysis: